Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder
|ClinicalTrials.gov Identifier: NCT00122070|
Recruitment Status : Completed
First Posted : July 21, 2005
Last Update Posted : June 10, 2008
The objective of this study is to quantitatively examine the efficacy of Seroquel (active ingredient quetiapine fumarate) in subjects with Borderline Personality Disorder (BPD). A secondary objective is to characterize the safety and tolerability of utilizing quetiapine in patients with Borderline Personality Disorder.
Investigator initiated, 6-week, non-placebo controlled, non-randomized, open-label, single drug, single-center, medication trial.
Volunteers (n = 15) diagnosed with Borderline Personality Disorder using the Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II).
Subjects with Borderline Personality Disorder are washed out of all other medications. The subjects are then given the study drug at a dose within the drug's known therapeutic range.
|Condition or disease||Intervention/treatment||Phase|
|Borderline Personality Disorder||Drug: Quetiapine Fumarate||Phase 3|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder|
|Study Start Date :||May 2005|
|Primary Completion Date :||September 2007|
|Study Completion Date :||May 2008|
Quetiapine at dosage of 50 to 150 mg
Drug: Quetiapine Fumarate
Dosage can vary from 50 to 150 mg at PI's discretion
Other Name: Seroquel
- Symptom Checklist 90 scale (SCL-90-R) [ Time Frame: 8 weeks ]
- Safety and tolerability will be measured at Baseline and weekly using the following scales: Simpson-Angus Extrapyramidal Side Effect Scale (SAS), Barnes Akathisia Scale (BAS), and Abnormal Involuntary Movement Scale (AIMS). [ Time Frame: 8 weeks ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00122070
|United States, New Jersey|
|University of Medicine and Dentistry of New Jersey - School of Osteopathic Medicine - Department of Psychiatry|
|Cherry Hill, New Jersey, United States, 08002-2000|
|Principal Investigator:||David J Rissmiller, DO||University of Medicine and Dentistry of New Jersey - School of Osteopathic Medicine|